rs1553493553
Variant summary
Our verdict is Pathogenic. Variant got 11 ACMG points: 11P and 0B. PVS1PM2PP5
The NM_001172509.2(SATB2):c.674G>A(p.Trp225*) variant causes a stop gained change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_001172509.2 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 11 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SATB2 | NM_001172509.2 | c.674G>A | p.Trp225* | stop_gained | Exon 6 of 11 | ENST00000417098.6 | NP_001165980.1 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 28
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
not provided Pathogenic:1
The W225X nonsense variant in the SATB2 gene is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay. The W225X variant is not observed in large population cohorts (Lek et al., 2016). Although this pathogenic variant has not been reported previously to our knowledge, its presence is consistent with the diagnosis of SATB2-associated syndrome in this individual. -
Chromosome 2q32-q33 deletion syndrome Uncertain:1
The heterozygous nonsense variant [c.674G>A; p.Trp225*] in the exon 6 of the SATB2 gene. Stop gain mutation leads to loss of normal protein function through early truncation and hence this mutation could be the likely cause of clinical condition. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at